Dacomitinib (PF2998...

Dacomitinib (PF299804)
Dacomitinib (PF299804)
Dacomitinib (PF299804)

Dacomitinib (PF299804)

Min.Order / FOB Price:Get Latest Price

1 Kilogram

Negotiable

  • Min.Order :1 Kilogram
  • Purity: 98%
  • Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram,Other

Keywords

Dacomitinib (PF299804) 1110813-31-4 C24H25ClFN5O2

Quick Details

  • Appearance:powder
  • Application:1110813-31-4
  • PackAge:as requested
  • ProductionCapacity:300|Kilogram|Month
  • Storage:store in cool, dry place
  • Transportation:by sea or by air

Superiority:

 
Dacomitinib (PF299804) Basic information
Biological activity Clinical Study References
Product Name: Dacomitinib (PF299804)
Synonyms: (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide;PF299804;(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide;Dacomitinib;PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804
CAS: 1110813-31-4
MF: C24H25ClFN5O2
MW: 469.9390032
EINECS: -0
Product Categories: Anti-cancer&immunity;Inhibitors
Mol File: 1110813-31-4.mol
Dacomitinib (PF299804) Structure
 
Dacomitinib (PF299804) Chemical Properties
density  1.344
 
Safety Information
MSDS Information
 
 
Dacomitinib (PF299804) Usage And Synthesis
Biological activity Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2.
Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.
Clinical Study Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing.
Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status.
Additionally, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
References #
#
Usage PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.
 
Dacomitinib (PF299804) Preparation Products And Raw materials
 

 

Details:

Exhibition in shanghai

We have clients throughout the world：

Professional service and rich experience make customers

feel at ease, adequate stock and fast delivery meet your

desire.

 

 

Our Laboratoy

We have our own independent lab test center：

This makes sure that our technology support is reliable

and authoritative.All of self-owned fine chemicals are

manufactured strictly in accordance with international

standard.,and also has scientific cooperation with local

colleges and institutes.

 

 

Our factory

High quality with competitive price：

We are manufacturer and can provide high quality products

with factory price.

 

 

Package  & Shipment

Fast and safe delivery：

Parcels can be sent out within 24 hours after payment.

Tracking number is available secure and discreet shipment.

You have various choices of transportation methods.

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View